Understanding your Recurrence Score® result

What do the numbers on my Oncotype DX Breast Recurrence Score® report mean?



A personalized measurement of the activity of certain genes in your breast cancer tissue. Distant Recurrence
Risk at 9 Years

With AI or TAM Alone

8%
95% CI (6%, 10%)

Likelihood that your breast cancer will return at a different site within 9 years.

Group Average Absolute
Chemotherapy (CT)
Benefit*

RS 11-25 All Ages

<1%
95% CI (-1%, 2%)

TAILORX

The potential benefit of adding chemotherapy to your treatment regimen.

In most situations, your doctor will prescribe endocrine therapy. The question is whether or not you may benefit from adding chemotherapy—that's where the Breast Recurrence Score® test can provide clarity.

How can my Recurrence Score result help inform my treatment decision?

Across multiple studies, a patient's potential benefit of chemotherapy, regardless of age1-3:

NO CHEMOTHERAPY BENEFIT (<1%)

(0-25)

CHEMOTHERAPY BENEFIT (>15%)
(26-100)

RS
result

For patients with Recurrence Score results between 0-25, there is a <1% difference in a patient's chance of distant recurrence when treated with endocrine therapy and chemotherapy vs when treated with endocrine therapy alone.¹⁻³

For patients with Recurrence Score results between 26-100, there is a significant benefit in adding chemotherapy to endocrine therapy starting at Recurrence Score 26.3

Al = aromatase inhibitor; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; TAM = tamoxifen. *CT benefit is defined as the difference in distant recurrence between patients treated with endocrine therapy only and patients treated with endocrine therapy and chemotherapy.

References: 1. Sparano et al. N Engl J Med. 2018. 2. Sparano et al. N Engl J Med. 2015. 3. Paik et al. J Clin Oncol. 2006. Oncotype DX, Oncotype DX Breast Recurrence Score, and Recurrence Score are trademarks of Genomic Health, Inc. © 2019 Genomic Health, Inc. All rights reserved. GHI11669_0619



Recurrence Score® results: Additional considerations for patients ≤50 years of age

When it comes to the benefits of chemotherapy (CT), does my age matter?


Further analysis showed that some patients ≤50 years of age may see benefit from chemotherapy based on a reduction in the likelihood of a distant recurrence¹:

Age	RS 0-10	RS 11-15	RS 16-20	RS 21-25	RS 26-100
>50 years	No CT Benefit (<1%)				>15% CT Benefit
≤50 years	No CT Benefit (<1%)		~1.6% CT Benefit	~6.5% CT Benefit	>15% CT Benefit

Chemotherapy benefit seen in younger patients beginning at Recurrence Score 16

My Recurrence Score result is between 16-25. Will I benefit from chemotherapy?

Estimated Chemotherapy Benefit for Patients ≤50 Years With Recurrence Score Results 11-25



Knowing your Recurrence Score result will help you and your doctor make the most informed treatment decision

References: 1. Sparano et al. N Engl J Med. 2018. 2. Sparano et al. N Engl J Med. 2015. 3. Paik et al. J Clin Oncol. 2006. 4. Sparano et al. N Engl J Med. 2019.

Genomic Health, "Making cancer care smarter," Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype IQ, and Recurrence Score are trademarks of Genomic Health, Inc.

© 2019 Genomic Health, Inc. All rights reserved. GHI11669_0619





